Cargando…
Clinicopathological Features and Significance of Epidermal Growth Factor Receptor Mutation in Surgically Resected Early-Stage Lung Adenocarcinoma
The clinicopathological presentation of early-stage lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutations has been seldom studied. Our study enrolled patients with stage I and II lung adenocarcinoma between January 2014 and December 2017 at the National Taiwan Universit...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9914247/ https://www.ncbi.nlm.nih.gov/pubmed/36766495 http://dx.doi.org/10.3390/diagnostics13030390 |
_version_ | 1784885622512549888 |
---|---|
author | Lu, Chao-Wen Lin, Mong-Wei Chiang, Xu-Heng Hsu, Hsao-Hsun Hsieh, Min-Shu Chen, Jin-Shing |
author_facet | Lu, Chao-Wen Lin, Mong-Wei Chiang, Xu-Heng Hsu, Hsao-Hsun Hsieh, Min-Shu Chen, Jin-Shing |
author_sort | Lu, Chao-Wen |
collection | PubMed |
description | The clinicopathological presentation of early-stage lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutations has been seldom studied. Our study enrolled patients with stage I and II lung adenocarcinoma between January 2014 and December 2017 at the National Taiwan University Hospital. Clinicopathological features and prognosis were retrospectively reviewed and analyzed depending on EGFR mutation status. EGFR mutations were detected in 622 (60%) out of 1034 patients. Compared to the group without EGFR mutations, the group with EGFR mutations had more patients above 65 years of age (p < 0.001), more non-lepidic histological subtypes (p < 0.001), higher CEA levels (p = 0.044), higher grade of pleural (p = 0.02) and lymphovascular (p = 0.001) invasion, higher histological grade (p < 0.001), and a more advanced pathological stage (p = 0.022). In multivariate analysis, there was no significant difference in PFS or OS between the EGFR mutant and wild-type groups. In subtype analysis, the tumors with an L858R mutation had a more lepidic predominant histological type (p = 0.019) and less lymphovascular invasion (p = 0.011). No significant differences in PFS or OS were detected between the exon 19 deletion and L858R mutation groups. In early-stage lung adenocarcinoma, EGFR mutation may be considered as a treatment response predictor for tyrosine kinase inhibitors, instead of a predictor of clinical prognosis. |
format | Online Article Text |
id | pubmed-9914247 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99142472023-02-11 Clinicopathological Features and Significance of Epidermal Growth Factor Receptor Mutation in Surgically Resected Early-Stage Lung Adenocarcinoma Lu, Chao-Wen Lin, Mong-Wei Chiang, Xu-Heng Hsu, Hsao-Hsun Hsieh, Min-Shu Chen, Jin-Shing Diagnostics (Basel) Article The clinicopathological presentation of early-stage lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutations has been seldom studied. Our study enrolled patients with stage I and II lung adenocarcinoma between January 2014 and December 2017 at the National Taiwan University Hospital. Clinicopathological features and prognosis were retrospectively reviewed and analyzed depending on EGFR mutation status. EGFR mutations were detected in 622 (60%) out of 1034 patients. Compared to the group without EGFR mutations, the group with EGFR mutations had more patients above 65 years of age (p < 0.001), more non-lepidic histological subtypes (p < 0.001), higher CEA levels (p = 0.044), higher grade of pleural (p = 0.02) and lymphovascular (p = 0.001) invasion, higher histological grade (p < 0.001), and a more advanced pathological stage (p = 0.022). In multivariate analysis, there was no significant difference in PFS or OS between the EGFR mutant and wild-type groups. In subtype analysis, the tumors with an L858R mutation had a more lepidic predominant histological type (p = 0.019) and less lymphovascular invasion (p = 0.011). No significant differences in PFS or OS were detected between the exon 19 deletion and L858R mutation groups. In early-stage lung adenocarcinoma, EGFR mutation may be considered as a treatment response predictor for tyrosine kinase inhibitors, instead of a predictor of clinical prognosis. MDPI 2023-01-20 /pmc/articles/PMC9914247/ /pubmed/36766495 http://dx.doi.org/10.3390/diagnostics13030390 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lu, Chao-Wen Lin, Mong-Wei Chiang, Xu-Heng Hsu, Hsao-Hsun Hsieh, Min-Shu Chen, Jin-Shing Clinicopathological Features and Significance of Epidermal Growth Factor Receptor Mutation in Surgically Resected Early-Stage Lung Adenocarcinoma |
title | Clinicopathological Features and Significance of Epidermal Growth Factor Receptor Mutation in Surgically Resected Early-Stage Lung Adenocarcinoma |
title_full | Clinicopathological Features and Significance of Epidermal Growth Factor Receptor Mutation in Surgically Resected Early-Stage Lung Adenocarcinoma |
title_fullStr | Clinicopathological Features and Significance of Epidermal Growth Factor Receptor Mutation in Surgically Resected Early-Stage Lung Adenocarcinoma |
title_full_unstemmed | Clinicopathological Features and Significance of Epidermal Growth Factor Receptor Mutation in Surgically Resected Early-Stage Lung Adenocarcinoma |
title_short | Clinicopathological Features and Significance of Epidermal Growth Factor Receptor Mutation in Surgically Resected Early-Stage Lung Adenocarcinoma |
title_sort | clinicopathological features and significance of epidermal growth factor receptor mutation in surgically resected early-stage lung adenocarcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9914247/ https://www.ncbi.nlm.nih.gov/pubmed/36766495 http://dx.doi.org/10.3390/diagnostics13030390 |
work_keys_str_mv | AT luchaowen clinicopathologicalfeaturesandsignificanceofepidermalgrowthfactorreceptormutationinsurgicallyresectedearlystagelungadenocarcinoma AT linmongwei clinicopathologicalfeaturesandsignificanceofepidermalgrowthfactorreceptormutationinsurgicallyresectedearlystagelungadenocarcinoma AT chiangxuheng clinicopathologicalfeaturesandsignificanceofepidermalgrowthfactorreceptormutationinsurgicallyresectedearlystagelungadenocarcinoma AT hsuhsaohsun clinicopathologicalfeaturesandsignificanceofepidermalgrowthfactorreceptormutationinsurgicallyresectedearlystagelungadenocarcinoma AT hsiehminshu clinicopathologicalfeaturesandsignificanceofepidermalgrowthfactorreceptormutationinsurgicallyresectedearlystagelungadenocarcinoma AT chenjinshing clinicopathologicalfeaturesandsignificanceofepidermalgrowthfactorreceptormutationinsurgicallyresectedearlystagelungadenocarcinoma |